Lexeo Therapeutics price target raised to $25 from $23 at Chardan
The Fly

Lexeo Therapeutics price target raised to $25 from $23 at Chardan

Chardan analyst Geulah Livshits raised the firm’s price target on Lexeo Therapeutics (LXEO) to $25 from $23 and keeps a Buy rating on the shares. The company reported Q3 results and announced it reached alignment with the FDA on registrational endpoints to support accelerated approval of its AAVrh10 GT LX2006 targeting Friedreich’s ataxia cardiomyopathy, the analyst tells investors in a research note.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App